Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...

Biotech firm CSL Behring has announced the four-year results from the pivotal HOPE-B study confirming the long-term ...

Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...

Danish pharma major Novo Nordisk has announced interim results from the Phase III FRONTIER3 trial of 70 children with ...

The US Food and Drug Administration (FDA) has issued several warning letters to pharmaceutical manufacturers in India and ...

Netherlands-based Bilthoven Biologicals, the Dutch subsidiary of the Serum Institute of India and a leading end-to-end ...

Shares of rare disease drug developer X4 Pharmaceuticals took a battering after it said it will restructure its workforce and ...

Alumis (Nasdaq: ALMS) and Acelyrin (Nasdaq: SLRN) have agreed to merge in an all-stock deal, creating a late-stage ...

Roche has reported positive results from its Phase III REGENCY trial of Gazyva (obinutuzumab) for the treatment of lupus ...

Kura Oncology and Japan’s Kyowa Kirin have announced that their menin inhibitor ziftomenib met the primary endpoint in a ...

Trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has accused one of the country’s largest compounders, Hims & Hers, of running a misleading multi-million dollar Super Bowl ...